Tayo Sanders

Company: Singular Immune

Job title: Chief Business Officer

Seminars:

Analyzing In Vivo Approaches, Delivery & Safety to Uncover their Future Potential 3:10 pm

Exploring the therapeutic potential of in vivo approaches, including in vivo and B-cell depletion to anticipate a future developments Assessing if the rules that govern cancer therapies are applicable to autoimmunity to effectively evaluate knockout strategies with lentiviral vectors or opportunities for redosing with mRNA Debating safety versus efficacy in the context of LNP and…Read more

day: Day One